Literature DB >> 9816124

Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.

A Sandoval1, U Consoli, W Plunkett.   

Abstract

Incorporation of fludarabine, 9-beta-d-arabinofuranosyl-2-fluoroadenine (F-ara-A), into replicating DNA inhibits further chain elongation and is the critical event in F-ara-A-mediated cytotoxicity. We have used the normal cellular process of nucleotide excision repair to create an opportunity for F-ara-A incorporation into the DNA of noncycling cells. Irradiation of quiescent lymphocytes with UV light (254 nm, 0. 5-30 J/m2) in the presence of [3H]F-ara-A produced a dose-dependent increase in F-ara-A monophosphate incorporation into DNA that reflected a 60-70% inhibition of DNA repair at 2 h. Lymphocytes pretreated with 3 micrometer F-ara-A for 2 h before irradiation with 0.5 or 2.0 J/m2 were incubated for 24 h in the presence or absence of F-ara-A. Morphological features of apoptosis and DNA cleavage into high molecular weight fragments were increased in cells treated with UV plus F-ara-A compared to those treated with UV or F-ara-A alone. FACScan analysis confirmed the morphological and biochemical results. A 2-h pulse of F-ara-A produced intracellular F-ara-ATP levels of 40 micrometer, and removal of F-ara-A from the media resulted in a monophasic elimination (r2 = 0.88) in F-ara-ATP levels with a half-life of 5.6 h. Lymphocytes undergoing apoptosis demonstrated a G0 DNA content, indicating that entry into the cell cycle was not required. This study demonstrates that F-ara-AMP is incorporated into DNA during UV-induced repair in quiescent lymphocytes and that this is associated with the inhibition of ongoing DNA repair and an increased incidence of apoptosis. Combinational therapies involving fludarabine with agents and modalities that initiate DNA repair may have clinical relevance in the treatment of human malignancies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816124

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

1.  Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.

Authors:  Alma Zecevic; Deepa Sampath; Brett Ewald; Rong Chen; William Wierda; William Plunkett
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 2.  The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance.

Authors:  Deepa Sampath; William Plunkett
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

Review 3.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

4.  Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.

Authors:  Rishi S Kotecha; Ronald W Stam; Priscilla Wander; Laurence C Cheung; Sandra S Pinhanҫos; Luke Jones; Mark Kerstjens; Susan T C J M Arentsen-Peters; Sajla Singh; Grace-Alyssa Chua; Patricia Garrido Castro; Pauline Schneider; M Emmy M Dolman; Bianca Koopmans; Jan J Molenaar; Rob Pieters; C Michel Zwaan
Journal:  Leukemia       Date:  2020-06-02       Impact factor: 11.528

5.  Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Authors:  Jeannine S McCune; Paolo Vicini; David H Salinger; Paul V O'Donnell; Brenda M Sandmaier; Claudio Anasetti; Donald E Mager
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-06       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 7.  Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.

Authors:  Syed Saqib Ali; Ruchika Raj; Tejinder Kaur; Brenna Weadick; Debasis Nayak; Minnsung No; Jane Protos; Hannah Odom; Kajal Desai; Avinash K Persaud; Joanne Wang; Rajgopal Govindarajan
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

8.  Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.

Authors:  Etienne Moussay; Valérie Palissot; Laurent Vallar; Hélène A Poirel; Thomas Wenner; Victoria El Khoury; Nasséra Aouali; Kris Van Moer; Bernadette Leners; François Bernardin; Arnaud Muller; Pascale Cornillet-Lefebvre; Alain Delmer; Caroline Duhem; Fernand Ries; Eric van Dyck; Guy Berchem
Journal:  Mol Cancer       Date:  2010-05-20       Impact factor: 27.401

9.  DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.

Authors:  Martha Rodriguez Sandoval; Kumudha Balakrishnan; Rajyalakshmi Luthra; Michael Keating; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2013-07-29

10.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

Authors:  Kensuke Kojima; Marina Konopleva; Teresa McQueen; Susan O'Brien; William Plunkett; Michael Andreeff
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.